I suspect that the FDA has already come up with some study parameters on the number of subjects and duration. These are likely too stringent and too expensive for RVX and Pfizer and they are trying to negotiate a shorter trial with less subjects and reduce the study cost. Can they cut that deal? Will they get some political help to push it through the FDA?